Please assess the completion status of the following clinical trial:

Trial Title: Xeloda and Bevacizumab to Treat Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient has given written informed consent prior to any study related procedure~2. Male and female aged 18 to 75 years~3. ECOG performance status 0 or 1~4. Histologically confirmed diagnostic of adenocarcinoma of the rectum \< 15 cm from anal verge~5. Clinical stage of T3, T4 with/without regional lymph node metastases, without metastatic disease~6. Disease evaluable by imaging techniques~7. No tumour haemorrhage in the week prior to start of study treatment~8. External derivation in symptomatic occlusive tumours~9. Not prior cancer treatment~10. Adequate bone marrow, hepatic and renal function, defined as:~    1. White blood cells ≥ 4 x 109 /l~   2. Absolute neutrophil count ≥ 1.5 x 109 /l~   3. Platelets ≥ 100 x 109 /l~   4. Haemoglobin ≥10 g/dl~   5. Bilirubin \< 1.25 x upper limit of normal~   6. Aspartate transaminase and alanine transaminase \< 2.5 x upper limit of normal~   7. Serum creatinine ≤ 106 µmol/l~11. Less than 10% weight loss~Exclusion Criteria:~1. Rectal cancer no amenable to resection~2. Any other malignancy which has been active or treated within the past 5 years , with the exception of in situ carcinoma of the cervix and non-melanoma skin lesions adequately treated~3. Pregnant or breast-feeding women~4. Women oh childbearing potential unless effective methods of contraception are used~5. No prior or concurrent significant medical conditions, including any of the following:~   * Cerebrovascular disease (including transient ischemic attack and stroke) within the past year~  * Cardiovascular disease, including the following:~  * Myocardial infarction within the past year~  * Uncontrolled hypertension while receiving chronic medication~  * Unstable angina~  * New York Heart Association class II-IV congestive heart failure~  * Serious cardiac arrhythmia requiring medication~6. Major trauma within the past 28 days~7. Serious nonhealing wound, ulcer, or bone fracture~8. Evidence of bleeding diathesis or coagulopathy~9. No lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medication~10. No evidence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug~11. No known dihydropyrimidine dehydrogenase deficiency~12. Major surgery in the 4 weeks prior to the start of study treatment~13. No concurrent chronic, daily treatment with aspirin (\> 325 mg/day)~14. More than 10 days since prior use of full-dose oral or parenteral anticoagulants for therapeutic purposes~15. No participation in another clinical trial with any investigational drug within 30 days prior to randomization or during study participation~16. No other medical history or condition that, in the opinion of the investigator, would preclude study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Bevacizumab & capecitabine & radiotheraphy (Type: EXPERIMENTAL): Bevacizumab 4 cycles each 15 days, the first 10 mg/kg and the rest of cycles with 5 mg/kg.~Radiotherapy 45 Gy starting on Bevacizumab 2nd cycle during 5 weeks, 1.8 Gy per day, 5 days at week.~Capecitabine 900 mg/m2 two times a day concomitant during radiotherapy period.

Based on this trial design, predict the completion outcome and termination type (if applicable).